InsiderPulseNo transactions found.
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $8.0M-7.7% | $8.7M-22.8% | $11.2M |
| Cost of revenue | $2.9M-5.8% | $3.1M-29.5% | $4.4M |
| Gross profit | $5.1M-8.9% | $5.5M-18.4% | $6.8M |
| Sales and marketing | $3.0M-60.4% | $7.5M-46.4% | $14.1M |
| General and administrative | $6.9M-32.9% | $10.3M-40.2% | $17.3M |
| Research and development | $1.8M-22.1% | $2.3M-8.8% | $2.5M |
| Transaction costs | $1.0M | — | — |
| Impairment of long-lived assets | $36K-95.4% | $777K-95.9% | $18.7M |
| Gain on disposal of assets, net | -$33K | — | $529K |
| Total operating expenses | $12.8M-38.9% | $20.9M-60.6% | $53.2M |
| Operating loss | -$7.7M+49.8% | -$15.4M+66.8% | -$46.4M |
| Interest income, net | -$14K+46.2% | -$26K-123.0% | $113K |
| Gain on changes in fair value of liability warrants | -$52K+98.7% | -$3.9M | — |
| Gain on extinguishment of debt | -$429K | — | — |
| Loss (gain) on foreign currency exchange, net | $51K+331.8% | -$22K-115.6% | $141K |
| Other | -$193K-58.2% | -$122K-1009.1% | -$11K |
| Loss before income tax provision | -$7.1M+37.4% | -$11.3M+75.7% | -$46.6M |
| Income tax expense | $39K-25.0% | $52K+113.7% | -$380K |
| Net loss | -$7.1M+37.4% | -$11.4M+75.4% | -$46.2M |
| Net loss per share - basic (in dollars per share) | -$14K+87.5% | -$111K-1.8% | -$109K |
| Net loss per share - diluted (in dollars per share) | -$14K+87.5% | -$111K-1.8% | -$109K |
| Shares used to compute basic net loss per share (in shares) | $515.6M+402.0% | $102.7M-75.8% | $424.4M |
| Shares used to compute diluted net loss per share (in shares) | $515.6M+402.0% | $102.7M-75.8% | $424.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026